Xencor Inc.

4 days ago · defenseworld.net

Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Valuation and Earnings This table compares Anika Therapeutics

20 days ago · businesswire.com

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.

2 months ago · zacks.com

Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.

2 months ago · zacks.com

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2 months ago · businesswire.com

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, to be held October 23-.

2 months ago · seekingalpha.com

Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near term.